Anti-Claudin 18.2 antibody and antibody-drug conjugate thereof
Provided are an antibody targeting Claudin 18.2, an antibody-drug conjugate, and use thereof in treatment of cancer. Also provided are a nucleotide encoding the Claudin 18.2 antibody, a polynucleotide combination, an expression vector, an expression vector combination, a pharmaceutical composition comprising the Caudill 18.2 antibody and the antibody-drug conjugate, and an application thereof in preparation of a medication for treatment or prevention of cancer.
1 . An anti-Claudin 18.2 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region have CDRs sequences identical to that of an antibody defined by the following sequences or obtained by 1-2 amino acid substitutions of the CDRs of the antibody defined by the following sequences:
(1) an amino acid sequence of a heavy chain variable region as shown in SEQ ID NO: 1; and
(2) an amino acid sequence of a light chain variable region as shown in SEQ ID NO: 2.
2 . The antibody or antigen-binding fragment thereof according to claim 1 , wherein:
(1) for the heavy chain variable region, CDR1 has an amino acid sequence as shown in SEQ ID NO: 3, 4, 5, 6 or 7 or obtained by 1 or 2 amino acid substitutions of SEQ ID NO: 3, 4, 5, 6 or 7; CDR2 has an amino acid sequence as shown in SEQ ID NO: 8, 9, 10, 11 or 12, or obtained by 1 or 2 amino acid substitutions of SEQ ID NO: 8, 9, 10, 11 or 12; and CDR3 has an amino acid sequence as shown in SEQ ID NO: 13, 14, 15, 16 or 17, or obtained by 1 or 2 amino acid substitutions of SEQ ID NO: 13, 14, 15, 16 or 17; and
(2) for the light chain variable region, CDR1 has an amino acid sequence as shown in SEQ ID NO: 18, 19, 20, 21 or 22 or obtained by 1 or 2 amino acid substitutions of SEQ ID NO: 18, 19, 20, 21 or 22; CDR2 has an amino acid sequence as shown in SEQ ID NO: 23, 24, 25, 26 or 27, or obtained by 1 or 2 amino acid substitutions of SEQ ID NO: 23, 24, 25, 26 or 27; and CDR3 has an amino acid sequence as shown in SEQ ID NO: 28, 29, 30, 31 or 32, or obtained by 1 or 2 amino acid substitutions of SEQ ID NO: 28, 29, 30, 31 or 32.
3 . The antibody or antigen-binding fragment thereof according to claim 2 , wherein,
(1) CDRs 1-3 of the heavy chain variable region have amino acid sequences of SEQ ID NOs: 3, 8 and 13 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 3, 8 and 13, and the CDRs 1-3 of the light chain variable region have amino acid sequences of SEQ ID NOs: 18, 23 and 28 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 18, 23 and 28;
(2) CDRs 1-3 of the heavy chain variable region have amino acid sequences of SEQ ID NOs: 4, 9 and 14 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 4, 9 and 14, and the CDRs 1-3 of the light chain variable region have amino acid sequences of SEQ ID NOs: 19, 24 and 29 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 19, 24 and 29;
(3) CDRs 1-3 of the heavy chain variable region have amino acid sequences of SEQ ID NOs: 5, 10 and 15 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 5, 10 and 15, and the CDRs 1-3 of the light chain variable region have amino acid sequences of SEQ ID NOs: 20, 25 and 30 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 20, 25 and 30;
(4) CDRs 1-3 of the heavy chain variable region have amino acid sequences of SEQ ID NOs: 6, 11 and 16 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 6, 11 and 16, and the CDRs 1-3 of the light chain variable region have amino acid sequences of SEQ ID NOs: 21, 26 and 31 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 21, 26 and 31; or
(5) CDRs 1-3 of the heavy chain variable region have amino acid sequences of SEQ ID NOs: 7, 12 and 17 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 7, 12 and 17, and the CDRs 1-3 of the light chain variable region have amino acid sequences of SEQ ID NOs: 22, 27 and 32 or obtained by 1 or 2 amino acid substitutions of SEQ ID NOs: 22, 27 and 32.
4 . The antibody or antigen-binding fragment thereof according to claim 1 , wherein:
(1) the heavy chain variable region has an amino acid sequence as shown in SEQ ID NO:
1, or comprises the same CDRs 1-3 as in SEQ ID NO: 1 and has an amino acid sequence having more than 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1; and
(2) the light chain variable region has an amino acid sequence as shown in SEQ ID NO: 2, or comprises the same CDRs 1-3 as in SEQ ID NO: 2 and has an amino acid sequence having more than 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2;
or
(3) the heavy chain has an amino acid sequence as shown in SEQ ID NO: 33; and
(2) (4) the light chain has an amino acid sequence as shown in SEQ ID NO: 34.
5 . The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen-binding fragment thereof includes a monoclonal antibody, Fab, Fab′, Fab′-SH, F(ab′) 2 , Fv, single chain Fv (scFv), bispecific antibody, multispecific antibody, chimeric antibody, humanized antibody or fusion protein comprising an antigen-binding fragment of an antibody.
6 . The antibody or antigen-binding fragment thereof according to claim 1 , further comprising a human or murine constant region.
7 . An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof according to claim 1 .
8 . The antibody-drug conjugate according to claim 7 , wherein the antibody-drug conjugate has a structure represented by formula (I):
Ab-L-D (I)
wherein:
Ab is the antibody or antigen-binding fragment thereof according to claim 1 ;
D is an active drug unit;
L is any linking group, which is covalently linked to the antibody or antigen-binding fragment thereof Ab and the active drug unit D, respectively;
wherein, Ab is linked to one or more active drug units D through one or more linking groups L.
9 . The antibody-drug conjugate according to claim 8 , wherein L is covalently linked to an amino residue or a thiol residue of the antibody Ab.
10 . The antibody-drug conjugate according to claim 8 , wherein L includes a cleavable linker and a non-cleavable linker.
11 . The antibody-drug conjugate according to claim 8 , wherein L comprises a structure selected from the group consisting of:
12 . The antibody-drug conjugate according to claim 8 , wherein the active drug unit D is selected from the group consisting of a cytotoxic molecule, cell differentiation factor, stem cell trophic factor, steroid drug, drug for the treatment of autoimmune diseases, anti-inflammatory drug, and drug for the treatment of infectious diseases.
13 . The antibody-drug conjugate according to claim 8 , wherein the active drug unit D has a structure selected from the group consisting of:
14 . The antibody-drug conjugate according to claim 8 , wherein the antibody-drug conjugate has a structure selected from the group consisting of:
wherein, p is an integer selected from 1, 2, 3, 4, 5, 6, 7, and 8, and q is an integer selected from 1, 2, 3, and 4.
15 . An isolated polynucleotide or combination thereof, encoding the antibody or antigen-binding fragment thereof according to claim 1 .
16 . A nucleic acid construct comprising the polynucleotide according to claim 15 .
17 . A host cell comprising the nucleic acid construct according to claim 16 .
18 . A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to claim 1 , and a pharmaceutically acceptable carrier.
19 . A method for producing an anti-Claudin 18.2 antibody, comprising culturing the host cell according to claim 17 under a condition suitable for expressing a vector encoding an anti-Claudin 18.2 antibody or an antigen-binding fragment thereof, and recovering the antibody or fragment.
20 . A method for treating cancer, comprising administering the antibody or antigen-binding fragment thereof according to claim 1 to a subject in need thereof.
21 . The antibody or antigen-binding fragment thereof according to claim 5 , wherein the antibody is a humanized monoclonal antibody.
22 . The antibody or antigen-binding fragment thereof according to claim 6 , wherein the constant region is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.
23 . The antibody-drug conjugate according to claim 9 , wherein L is covalently linked to a thiol residue formed by breaking an interchain disulfide bond of the antibody Ab.
24 . The antibody-drug conjugate according to claim 10 , wherein the cleavable linker includes a peptide unit comprising 2 to 20 amino acids.
25 . The antibody-drug conjugate according to claim 24 , wherein the peptide unit is selected from the group consisting of-valine-citrulline-(-Val-Cit-),-glycine-glycine-phenylalanine-glycine-(-Gly-Gly-Phe-Gly-),-valine-alanine-(-Val-Ala-),-valine-lysine-(-Val-Lys-),-valine-arginine-(-Val-Arg-),-phenylalanine- citrulline-(-Phe-Cit-),-phenylalanine-lysine-(-Phe-Lys-),-phenylalanine-arginine-(-Phe-Arg-) and a combination thereof.
26 . The antibody-drug conjugate according to claim 12 , wherein the cytotoxic molecule is selected from the group consisting of a tubulin inhibitor or a DNA damaging agent.
27 . The antibody-drug conjugate according to claim 26 , wherein the tubulin inhibitor is selected from the group consisting of a cytotoxic molecule of dolastatins and auristatins, a cytotoxic molecule of maytansines; the DNA damaging agent is selected from the group consisting of calicheamicins, duocarmycins, anthramycin derivative pyrrolobenzodiazepine (PBD), camptothecins and a derivative thereof, and SN-38.
28 . The antibody-drug conjugate according to claim 27 , wherein the cytokine molecule of auristatins is selected from the group consisting of MMAE, MMAF, or a derivative thereof; and the cytotoxic molecule of maytansines is selected from the group consisting of DM1, DM4, or a derivative thereof.
29 . The nucleic acid construct according to claim 16 , wherein the nucleic acid construct is a vector.
30 . The host cell according to claim 17 , wherein the cell is selected from the group consisting of a prokaryotic cell, eukaryotic cell, yeast cell, mammalian cell, E. coli cell or CHO cell, NS0 cell, Sp2/0 cell, and BHK cell.
31 . The method according to claim 20 , wherein the cancer is a solid tumor.
32 . The method according to claim 31 , wherein the solid tumor is selected from the group consisting of gastric cancer and pancreatic cancer.